A phase II clinical study is presently investigating the efficacy of anti-CTLA-4 in GBM patients post-radiation and chemotherapy, comparing temozolomide treatment alone with temozolomide combined with ipilimumab (anti-CTLA-4) [109]. Here, CTLA4 is linked to glioblastoma.